Fibrinogen Is A Coagulation Marker Associated With The Prognosis Of Endometrial Cancer.
clinicopathological characteristics
endometrial carcinoma
hemostatic markers
survival
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
accepted:
14
10
2019
entrez:
11
12
2019
pubmed:
11
12
2019
medline:
11
12
2019
Statut:
epublish
Résumé
The present study aimed to identify coagulation markers with prognostic value in the setting of surgically treated endometrial cancer. A total of 942 patients with endometrial cancer who underwent surgery were included in the study. The preoperative prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), prothrombin time activity (PTA), fibrinogen and D-dimer values were analyzed to determine their potential associations with clinicopathological characteristics. Survival analysis was performed using the Kaplan-Meier method, p-values were calculated using the log-rank text, and the prognostic factors were evaluated using Cox's proportional hazards regression model. The preoperative plasma fibrinogen and D-dimer concentrations were significantly different among patients with different ages, pre/post-menopausal status, International Federation of Obstetrics and Gynecology Association (FIGO) stage, tumor grade, depth of myometrial invasion, histological type and lymphatic vessel space invasion. Fibrinogen level was also asscoiated with body mass index (BMI) and comorbidities, and D-dimer level was asscoiated with preoperative radiotherapy and chemotherapy. APTT was different in patients in pre/post-menopausal status and with or without comorbidities. PTA was asscoiated with BMI and lymphovascular invasion. TT was different between different age groups, different menopause status groups, as well as different FIGO stage groups. A multivariate analysis identified high fibrinogen levels (>3.25 g/L) as an independent prognostic factor for overall survival (HR=1.807; 95% CI=1.003-3.253; p=0.049). High pretreatment fibrinogen levels are associated with poor overall survival and represent a valuable independent prognostic factor in patients with endometrial cancer. PT, aPTT, TT, PTA and D-dimer levels cannot be used as independent prognostic factors for endometrial cancer.
Identifiants
pubmed: 31819491
doi: 10.2147/OTT.S222813
pii: 222813
pmc: PMC6875273
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9947-9956Informations de copyright
© 2019 Li et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Gynecol Oncol. 2017 Mar;28(2):e11
pubmed: 27894164
J Obstet Gynaecol. 2016;36(3):353-8
pubmed: 26470941
Biosci Rep. 2013 Sep 04;33(5):null
pubmed: 23889169
J Breast Cancer. 2017 Sep;20(3):254-263
pubmed: 28970851
Cancer Res. 2010 Apr 1;70(7):2634-43
pubmed: 20233870
Blood. 2000 Nov 15;96(10):3302-9
pubmed: 11071621
Cancer. 1996 Mar 15;77(6):1115-21
pubmed: 8635132
Br J Cancer. 2010 Mar 16;102(6):952-6
pubmed: 20160724
Am J Pathol. 2003 Jun;162(6):1747-57
pubmed: 12759232
Semin Thromb Hemost. 2019 Jun;45(4):413-422
pubmed: 31041799
Cancer Manag Res. 2018 Oct 04;10:4203-4216
pubmed: 30323676
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J BUON. 2017 Mar-Apr;22(2):462-467
pubmed: 28534370
Gynecol Oncol. 2010 Nov;119(2):309-13
pubmed: 20688365
Clin Cancer Res. 2000 Jan;6(1):166-71
pubmed: 10656446
Br J Cancer. 2008 Oct 7;99(7):1034-9
pubmed: 18781175
Eur J Obstet Gynecol Reprod Biol. 2016 Jun;201:89-93
pubmed: 27085144
J Clin Invest. 1985 Jan;75(1):11-8
pubmed: 3965498
Gastroenterol Res Pract. 2018 Jun 3;2018:3450981
pubmed: 29967637
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Pancreatology. 2019 Mar;19(2):346-351
pubmed: 30638854
Blood. 2003 Feb 15;101(4):1243-8
pubmed: 12393393
Gynecol Oncol. 2014 Aug;134(2):385-92
pubmed: 24905773
Curr Opin Hematol. 2014 Sep;21(5):423-9
pubmed: 25054907
Cancer Med. 2019 Jun;8(6):2919-2929
pubmed: 31050218
Curr Opin Hematol. 2010 May;17(3):225-9
pubmed: 20375889
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
World Neurosurg. 2019 Jan;121:e621-e629
pubmed: 30292037
Int J Clin Oncol. 2018 Dec;23(6):1070-1075
pubmed: 30168089
J Thromb Haemost. 2013 Feb;11(2):223-33
pubmed: 23279708
Urology. 2010 Mar;75(3):608-14
pubmed: 19683801
Oncol Lett. 2017 Jun;13(6):4669-4674
pubmed: 28599468
PLoS One. 2015 Jun 24;10(6):e0130640
pubmed: 26107255
Cancer Med. 2019 Jul;8(7):3447-3452
pubmed: 31091022
Transl Oncol. 2019 Jul;12(7):996-1004
pubmed: 31125760
World J Gastroenterol. 2018 Nov 28;24(44):5046-5056
pubmed: 30510379
Semin Thromb Hemost. 2015 Oct;41(7):756-64
pubmed: 26408922
Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
pubmed: 8281615